Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

82.76EUR
11:35am EDT
Change (% chg)

€0.18 (+0.22%)
Prev Close
€82.58
Open
€82.42
Day's High
€83.26
Day's Low
€82.30
Volume
2,028,464
Avg. Vol
2,442,337
52-wk High
€92.97
52-wk Low
€66.72

Latest Key Developments (Source: Significant Developments)

Sanofi initiates phase 2 clinical trial
Tuesday, 14 Feb 2017 08:00am EST 

Sanofi SA :Sanofi initiates phase 2 clinical trial to evaluate therapy for genetic form of parkinson's disease.  Full Article

Sanofi nearing deal to sell some over-the-counter products to Ipsen for about 100 mln euros- Bloomberg, citing source
Sunday, 12 Feb 2017 08:43pm EST 

: Sanofi nearing agreement to sell some over-the-counter products to Ipsen; deal may be announced as soon as Monday- Bloomberg, citing source .Deal could be valued at almost 100 million euros- Bloomberg, citing source.  Full Article

Sanofi starts phase 3 trial of pompe disease treatment
Friday, 4 Nov 2016 08:00am EDT 

Sanofi Sa : Sanofi genzyme begins pivotal phase 3 trial of neogaa investigational second-generation therapy for pompe disease .Sanofi genzyme begins pivotal phase 3 trial of neogaa investigational second-generation therapy for pompe disease.  Full Article

Regeneron and Sanofi receive complete response letter from FDA for Sarilumab
Friday, 28 Oct 2016 02:35pm EDT 

Sanofi Sa : Regeneron and sanofi receive complete response letter from fda for sarilumab, an investigational treatment for rheumatoid arthritis . Sanofi says sanofi and regeneron remain committed to development of sarilumab and providing therapy to ra patients in u.s. As quickly as possible . Sanofi -if approved by fda, sarilumab would be commercialized by regeneron and sanofi genzyme, specialty care global business unit of sanofi .Sanofi - crl refers to certain deficiencies identified during gmp inspection of facility in france where sarilumab is filled and finished.  Full Article

Regeneron advised by Sanofi that manufacturing deficiencies have been raised by U.S. FDA
Friday, 28 Oct 2016 06:14am EDT 

Regeneron Pharmaceuticals Inc : Regeneron says it was advised by its collaborator, Sanofi, that manufacturing deficiencies have been raised by U.S. FDA during inspection of a Sanofi facility . Regeneron pharmaceuticals says sarilumab biologics license application with U.S. FDA expected action date of October 30, 2016 - SEC filing . Regeneron says given CGMP status of Sanofi's facility is under review by FDA, it is unclear how situation may impact timing of potential approval of sarilumab . Regeneron says FDA has completed a pre-approval inspection of regeneron's sarilumab manufacturing facility . Regeneron says deficiencies raised by FDA during good manufacturing practice inspection of sanofi facility that conducts 'fill and finish' activities for sarilumab .Regeneron says no form 483 was issued in connection with inspection.  Full Article

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 07:05am EDT 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Sanofi reports open market purchase of 450,000 shares of Myokardia
Wednesday, 5 Oct 2016 09:00am EDT 

Sanofi SA : Sanofi reports open market purchase of 450,000 shares Of Myokardia Inc for $15/Share on Oct 3, 2016 .Sanofi's open market purchase of 450,000 shares of myokardia inc made on Oct 3 represents an indirect ownership in Myokardia.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 08:00am EDT 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

Sanofi says BARDA grants $43.2 million to Sanofi Pasteur for Zika
Monday, 26 Sep 2016 11:05am EDT 

Sanofi : BARDA grants $43.2 million usd to Sanofi Pasteur for Zika . Beyond funding provided by BARDA for two phase i/ii clinical trials, there is an option for continuing support through phase iii . BARDA and U.S. Department of health and human services has agreed to a proposal to fund manufacture of Zika vaccine for phase ii development ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

U.S. Department of health and human services says BARDA awards funding to Sanofi Pasteur for Zika vaccine
Monday, 26 Sep 2016 10:36am EDT 

U.S. department of health and human services: U.S. Department Of Health And Human Services says contract includes an option for up to an additional $130.45 million to fund phase 3 clinical trials . U.S. Department Of Health And Human Services says BARDA awards funding to speed development of Zika vaccine ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

BRIEF-Paulson & Co cuts share stake in Teva Pharmaceutical, Sanofi

* Paulson & Co Inc cuts share stake in Teva Pharmaceutical Industries Ltd by 38.7 percent to 6.7 million sponsored ADR - SEC filing